Liver Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with liver cirrhosis (scarring of the liver), confirmed through methods such as an elastography scan, symptoms, a biopsy, or imaging scans.
- People aged 18 to 84 years old.
- People who are willing and able to provide written consent to take part.
Who may not be able to join:
- People who are unable to have an MRI scan, for example because they have certain metal implants or devices in their body, or because they experience severe claustrophobia (fear of enclosed spaces).
- People who are pregnant.
- People who have a condition called primary sclerosing cholangitis (PSC), which is a disease that causes scarring of the bile ducts — (confirm with trial site).
- People who have a liver condition caused by blood vessel problems (confirm with trial site).
- People who were born with a condition that causes abnormal scarring in the liver (confirm with trial site).
- People who have previously been diagnosed with liver cancer (hepatocellular carcinoma).
- People who have previously had a liver transplant.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Mattias Ekstedt, MD, PhD, Linkoeping University
Phone: 0046709296267
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Lesion at high risk for hepatocellular carcinoma (HCC) - (LI RADS 4-5); Lesion at high risk for hepatocellular carcinoma (HCC) - (LI RADS 4-5); Lesion at high risk for hepatocellular carcinoma (HCC) - (LI RADS 4-5); Lesion at high risk for hepatocellular carcinoma (HCC) - (LI RADS 4-5); Lesion at high risk for hepatocellular carcinoma (HCC) - (US LI RADS 3); Lesion at high risk for hepatocellular carcinoma (HCC) - (US LI RADS 3); Lesion at high risk for hepatocellular carcinoma (HCC) - (US LI RADS 3); Lesion at high risk for hepatocellular carcinoma (HCC) - (US LI RADS 3); The Muscle Assessmen...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.